Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis (original) (raw)

• Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10:403–9.
  Article CAS PubMed Google Scholar
• Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl. 1982;668:49–59.
  CAS PubMed Google Scholar
• Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol. 1989;42(3):257–67.
  Article CAS PubMed Google Scholar
• Lazzeri C, Valente S, Chiostri M, Sori A, Bernardo P, Gensini GF. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol. 2010;138(2):206–9.
  Article PubMed Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701.
  Article CAS PubMed Google Scholar
• Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164(14):1546–51.
  Article CAS PubMed Google Scholar
• Testa A, Prudente S, Leonardis D, et al. A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. Nutr Metab Cardiovasc Dis. 2015;25(12):1087–94.
  Article CAS PubMed Google Scholar
• Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout-influence of alcohol intake and body weight. Br J Rheumatol. 1994;33:731–4.
  Article CAS PubMed Google Scholar
• Takahashi S, Moriwaki Y, Tsutsumi Z, Yamakita J, Yamamoto T, Hada T. Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. Metabolism. 2001;50:393–8.
  Article CAS PubMed Google Scholar
• Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.
  Article CAS PubMed Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–87.
  Article CAS PubMed Google Scholar
• Kawashiri MA, Yamagishi M, Sakamoto T, et al. COSMOS Investigators. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Ther. 2013;31(6):335–43.
  Article CAS PubMed Google Scholar
• Wiliński J, Dabrowski M. Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3227 patients. Przegl Lek. 2013;70(6):373–6.
  PubMed Google Scholar
• Sahebkar A, Rathouska J, Simental-Mendía LE, Nachtigal P. Statin therapy and plasma cortisol concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;103:17–25.
  Article PubMed Google Scholar
• Sahebkar A, Simental-Mendía LE, Pedone C, et al. Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. Br J Clin Pharmacol. 2016;81(5):807–18.
  Article CAS PubMed Google Scholar
• Sahebkar A, Serban C, Mikhailidis DP, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, et al. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost. 2015;114(3):546–57.
  Article PubMed Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
  Article PubMed PubMed Central Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. London: The Cochrane Collaboration; 2009.
• Borenstein M, Hedges L, Higgins J, et al. Comprehensive meta-analysis. Version 2. Englewood; Biostat: 2005.
• Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. West Sussex: Wiley; 2000.
  Google Scholar
• Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res. 2015;60:50–73.
  Article CAS PubMed Google Scholar
• Greenhouse J, Iyengar S. Sensitivity analyses and diagnostics. In: Cooper HM, Hedges LV, editors. The handbook of research synthesis. New York: Russell Sage Foundation; 1994.
  Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
  Article CAS PubMed Google Scholar
• Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effects of atorvastatin on oxidative stress in chronic kidney disease. Nephrology (Carlton). 2015. doi:10.1111/nep.12502.
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism. 2005;54(8):1065–74.
  Article CAS PubMed Google Scholar
• Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels. 2008;23(2):91–5.
  Article PubMed Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, GREACE Study Collaborative Group, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis. 2004;43(4):589–99.
  Article CAS PubMed Google Scholar
• Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34(6):1281–6.
  Article CAS PubMed Google Scholar
• Gleim G, Ballantyne CM, Liu N, Thompson-Bell S, McCrary Sisk C, Pasternak RC, et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol. 2009;16(2):90–7.
  Google Scholar
• Tam LS, Li EK, Shang Q, et al. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scand J Rheumatol. 2011;40(6):411–21.
  Article CAS PubMed Google Scholar
• Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214(1):151–7.
  Article CAS PubMed Google Scholar
• Palomäki A, Malminiemi K, Metsä-Ketelä T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Lett. 1997;410(2–3):254–8.
  Article PubMed Google Scholar
• Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, et al. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. Eur J Gastroenterol Hepatol. 2014;26(7):781–7.
  Article CAS PubMed Google Scholar
• Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes Metab. 2010;12(11):983–93.
  Article CAS PubMed Google Scholar
• Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994;74(2):149–54.
  Article CAS PubMed Google Scholar
• McKenney J, Bays H, Gleim G, Mitchel Y, Kuznetsova O, Sapre A, et al. Safety and tolerability of extended-release niacin-laropiprant: pooled analyses for 11,310 patients in 12 controlled clinical trials. J Clin Lipidol. 2015;9(3):313–25.
  Article PubMed Google Scholar
• Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med. 2001;111(5):390–400.
  Article CAS PubMed Google Scholar
• Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635–40.
  Article CAS PubMed Google Scholar
• Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA. 1993;270(3):354–9.
  Article CAS PubMed Google Scholar
• Kose E, An T, Kikkawa A, Matsumoto Y, Hayashi H. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. Biol Pharm Bull. 2014;37(2):226–31.
  Article CAS PubMed Google Scholar
• Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157(2):255–7.
  Article PubMed Google Scholar
• Ogata N, Fujimori S, Oka Y, Kaneko K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010;29(4–6):321–4.
  Article CAS PubMed Google Scholar